Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo

@inproceedings{Schwab2014AfatinibDR,
  title={Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo},
  author={Carlton L. Schwab and Stefania Bellone and Diana P English and Dana Marie Roque and S Burguillos L{\'o}pez and Emiliano Cocco and Roberta Nicoletti and Ileana Bortolomai and Elena Bonazzoli and Elena Ratner and D A Silasi and Masoud Azodi and Peter Edward Schwartz and Thomas J. Rutherford and Alessandro D Santin},
  booktitle={British Journal of Cancer},
  year={2014}
}
Background:Uterine serous carcinomas (USCs) are an aggressive form of uterine cancer that may rely on HER2/neu amplification as a driver of proliferation. The objective of this paper is to assess the sensitivity of USC cell lines with and without HER2/neu gene amplification to afatinib, an irreversible ErbB tyrosine kinase inhibitor, and to test the efficacy of afatinib in the treatment of HER2-amplified USC xenografts.Methods:Eight of fifteen primary USC cell lines (four with HER2… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Similar Papers

Loading similar papers…